Last year, Neumann and his group advocated for a law to cap the price of epinephrine auto-injectors ... A company called ...

Amneal announced the advancement of two key strategic initiatives. Amneal has received approval from the Food and Drug Administration for exenatide, which is the company’s first generic ...

Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus ...

Gov. Kathy Hochul announced Thursday she had signed legislation aimed at making epinephrine — currently the only drug capable of preventing a fatal allergic reaction — more affordable.

A replay of the webcast will be available following the event. Source: Amneal Pharmaceuticals, Inc. The views and opinions expressed herein are the views and opinions of the author and do not ...

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist BRIDGEWATER ...

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the consensus of $0.14. The company reported sales of $702.47 ...